{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-072706","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.521670+00:00","generated_at":"2026-06-04T11:18:53.951749+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Madrigal raises ~$574M in public offering for Rezdiffra launch","bullets":["Offering of 750,000 shares at $260/share and 1,557,692 pre-funded warrants at $259.9999 each.","Net proceeds estimated at ~$574M; underwriters have 30-day option for up to 346,153 additional shares.","Proceeds to fund commercial launch of Rezdiffra (resmetirom) in the U.S. and for general corporate purposes.","Closing expected March 21, 2024; lock-up agreements for directors and officers for 60 days.","Underwriters include Goldman Sachs, Jefferies, Cowen, Evercore, Piper Sandler."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-072706","json":"https://secwatch.observer/filing/0001193125-24-072706.json","markdown":"https://secwatch.observer/filing/0001193125-24-072706.md","text":"https://secwatch.observer/filing/0001193125-24-072706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524072706/0001193125-24-072706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524072706/d774533d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:18:53.951749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a9d4d3d4ef259657552d35b27d76aee3bf6cf5c","claim":"MADRIGAL PHARMACEUTICALS, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler & Co valued at approximately $574.0 million (effective 2024-03-18).","evidence_excerpt":"On March 18, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler & Co, as representatives of the several underwriters named therein (the “Underwriters”), for the sale of (i) 750,000 shares of common stock (the “Shares”) of the Company, $0.0001 par value per share (the “Common Stock”), and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,557,692 shares of Common Stock in an underwritten public offering (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524072706/0001193125-24-072706-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC, Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler & Co"},{"label":"Value","value":"approximately $574.0 million"},{"label":"Effective","value":"2024-03-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}